WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005123775) ANTIBODIES SPECIFIC FOR SOLUBLE AMYLOID BETA PEPTIDE PROTOFIBRILS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/123775    International Application No.:    PCT/SE2005/000993
Publication Date: 29.12.2005 International Filing Date: 21.06.2005
IPC:
C07K 16/18 (2006.01), A61K 39/395 (2006.01), A61P 25/28 (2006.01), C07K 14/47 (2006.01)
Applicants: BIOARCTIC NEUROSCIENCE AB [SE/SE]; Uppsala Science Park, Box 105, S-75103 Uppsala (SE) (For All Designated States Except US).
GELLERFORS, Pär [SE/SE]; (SE) (For US Only).
LANNFELT, Lars [SE/SE]; (SE) (For US Only)
Inventors: GELLERFORS, Pär; (SE).
LANNFELT, Lars; (SE)
Agent: DR LUDWIG BRANN PATENTBYRÅ AB; Box 17192, (Västgötagatan 2), S-10462 Stockholm (SE)
Priority Data:
0401601-0 21.06.2004 SE
Title (EN) ANTIBODIES SPECIFIC FOR SOLUBLE AMYLOID BETA PEPTIDE PROTOFIBRILS AND USES THEREOF
(FR) ANTICORPS SPECIFIQUES DESTINES A DES PROTOFIBRILLES PEPTIDIQUES AMYLOIDES BETA ET UTILISATIONS ASSOCIEES
Abstract: front page image
(EN)The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.
(FR)L'invention concerne le développement d'anticorps se liant de manière spécifique à la protéine amyloïde bêta (Abêta) dans sa conformation de protofibrille. L'invention concerne également des procédés d'utilisation des anticorps de protofibrilles anti-Abêta, aux fins de diagnostic ou de traitement de la maladie d'Alzheimer, du syndrome de Down, de la démence à corps de Lewy, de la démence vasculaire et d'autres troubles neurodégénératifs. De plus, l'invention concerne l'utilisation des anticorps de protofibrilles anti-Abêta, aux fins de criblage et d'identification de substances modulant l'activité ou la formation de protofibrilles in vitro<i> </i>ou<i> </i>in vivo. L'invention concerne enfin des procédés de synthèse des antigènes purs de protofibrilles d'Abêta, ainsi qu'un procédé de stabilisation de protofibrilles d'Abêta.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)